Dr.Satish Chadha, C14378
Prospective study to recruit 100 participants, single centre, receiving anti- VEFG treatment between January and September 2018, to evaluate the psychological impact of anti VEGF treatment.
Anxiety and depression are regarded as the most frequent mental health problems among people with AMD specifically. There is evidence that AMD patients are likely to be depressed and anxious as a consequence of limitations imposed by vision loss and some to suggest that the process of injections contribute. Depression would be an additional source of disability for these patients and can compromise the response to the treatment and medical outcomes.
The questionnaire developed to evaluate includes 1) 7Item anxiety scale ( GAD-7) which is valid and
efficient tool for screening for GAD, and patient health Questionnaire (PHQ-2) for depression.
Preliminary results of 23 patients shows 17.4% ( 9.6%-30.1%) on GAD-7 Score and 0% scored on PHQ-2 for depression.
Other parameters will also be analysed.
Leave a Comment